BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 34477310)

  • 21. Peripheral T-cell lymphomas of follicular T-helper cell derivation with Hodgkin/Reed-Sternberg cells of B-cell lineage: both EBV-positive and EBV-negative variants exist.
    Nicolae A; Pittaluga S; Venkataraman G; Vijnovich-Baron A; Xi L; Raffeld M; Jaffe ES
    Am J Surg Pathol; 2013 Jun; 37(6):816-26. PubMed ID: 23598959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.
    Park SI; Horwitz SM; Foss FM; Pinter-Brown LC; Carson KR; Rosen ST; Pro B; Hsi ED; Federico M; Gisselbrecht C; Schwartz M; Bellm LA; Acosta M; Advani RH; Feldman T; Lechowicz MJ; Smith SM; Lansigan F; Tulpule A; Craig MD; Greer JP; Kahl BS; Leach JW; Morganstein N; Casulo C; Shustov AR;
    Cancer; 2019 May; 125(9):1507-1517. PubMed ID: 30694529
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Maura F; Dodero A; Carniti C; Bolli N; Magni M; Monti V; Cabras A; Leongamornlert D; Abascal F; Diamond B; Rodriguez-Martin B; Zamora J; Butler A; Martincorena I; Tubio JMC; Campbell PJ; Chiappella A; Pruneri G; Corradini P
    Haematologica; 2021 Nov; 106(11):2918-2926. PubMed ID: 33054126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified.
    Kawamoto K; Miyoshi H; Yanagida E; Yoshida N; Kiyasu J; Kozai Y; Morikita T; Kato T; Suzushima H; Tamura S; Muta T; Kato K; Eto T; Seki R; Nagafuji K; Sone H; Takizawa J; Seto M; Ohshima K
    Eur J Haematol; 2017 May; 98(5):459-466. PubMed ID: 28129454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proteomic profiling identifies outcome-predictive markers in patients with peripheral T-cell lymphoma, not otherwise specified.
    Ludvigsen M; Bjerregård Pedersen M; Lystlund Lauridsen K; Svenstrup Poulsen T; Hamilton-Dutoit SJ; Besenbacher S; Bendix K; Møller MB; Nørgaard P; d'Amore F; Honoré B
    Blood Adv; 2018 Oct; 2(19):2533-2542. PubMed ID: 30291111
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum IgA level, monocyte count, and international prognostic index are independently associated with overall survival in patients with HTLV-I-negative nodal peripheral T cell lymphoma.
    Kato A; Imai Y; Aoki K; Tabata S; Matsushita A; Hashimoto H; Takahashi T; Ishikawa T
    Ann Hematol; 2014 Jul; 93(7):1185-91. PubMed ID: 24526138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters.
    Lemonnier F; Couronné L; Parrens M; Jaïs JP; Travert M; Lamant L; Tournillac O; Rousset T; Fabiani B; Cairns RA; Mak T; Bastard C; Bernard OA; de Leval L; Gaulard P
    Blood; 2012 Aug; 120(7):1466-9. PubMed ID: 22760778
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma.
    Ghione P; Faruque P; Mehta-Shah N; Seshan V; Ozkaya N; Bhaskar S; Yeung J; Spinner MA; Lunning M; Inghirami G; Moskowitz A; Galasso N; Ganesan N; van der Weyden C; Ruan J; Prince HM; Trotman J; Advani R; Dogan A; Horwitz S
    Blood Adv; 2020 Oct; 4(19):4640-4647. PubMed ID: 33002132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical significance of enhancer of zeste homolog 2 and histone deacetylases 1 and 2 expression in peripheral T-cell lymphoma.
    Zhang H; Lv H; Jia X; Hu G; Kong L; Zhang T; Li L; Pan Y; Zhai Q; Meng B; Wang X; Wang H; Wang X
    Oncol Lett; 2019 Aug; 18(2):1415-1423. PubMed ID: 31423206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathologic analysis of peripheral T-cell lymphoma, follicular variant, and comparison with angioimmunoblastic T-cell lymphoma: Bcl-6 expression might affect progression between these disorders.
    Miyoshi H; Sato K; Niino D; Arakawa F; Kimura Y; Kiyasu J; Takeuchi M; Yoshida M; Okada Y; Nakamura Y; Sugita Y; Ohshima K
    Am J Clin Pathol; 2012 Jun; 137(6):879-89. PubMed ID: 22586046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clinical significance of activated p-AKT expression in peripheral T-cell lymphoma.
    Hong JY; Hong ME; Choi MK; Chang W; Do IG; Jo JS; Jung SH; Park S; Kim SJ; Ko YH; Kim WS
    Anticancer Res; 2015 Apr; 35(4):2465-74. PubMed ID: 25862915
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic Utility of SOX4 Expression in Adult T-Cell Leukemia/Lymphoma.
    Nasu A; Gion Y; Nishimura Y; Nishikori A; Sakamoto M; Egusa Y; Fujita A; Yoshino T; Sato Y
    Diagnostics (Basel); 2021 Apr; 11(5):. PubMed ID: 33923245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of multiple subclones in peripheral T-cell lymphoma, not otherwise specified with genomic aberrations.
    Yoshida N; Umino A; Liu F; Arita K; Karube K; Tsuzuki S; Ohshima K; Seto M
    Cancer Med; 2012 Dec; 1(3):289-94. PubMed ID: 23342278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathological analysis in PTCL-NOS with CADM1 expression.
    Kato T; Miyoshi H; Kobayashi S; Yoshida N; Imaizumi Y; Seto M; Uchimaru K; Miyazaki Y; Ohshima K
    Virchows Arch; 2017 Nov; 471(5):659-666. PubMed ID: 28940014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of prognostic factors in peripheral T-cell lymphoma: prognostic value of serum albumin and mediastinal lymphadenopathy.
    Chihara D; Oki Y; Ine S; Yamamoto K; Kato H; Taji H; Kagami Y; Yatabe Y; Nakamura S; Morishima Y
    Leuk Lymphoma; 2009 Dec; 50(12):1999-2004. PubMed ID: 19860627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The gene expression profile and cell of origin of canine peripheral T-cell lymphoma.
    Owens E; Harris L; Harris A; Yoshimoto J; Burnett R; Avery A
    BMC Cancer; 2024 Jan; 24(1):18. PubMed ID: 38166662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peripheral T-cell lymphoma with follicular T-cell markers.
    Rodríguez-Pinilla SM; Atienza L; Murillo C; Pérez-Rodríguez A; Montes-Moreno S; Roncador G; Pérez-Seoane C; Domínguez P; Camacho FI; Piris MA
    Am J Surg Pathol; 2008 Dec; 32(12):1787-99. PubMed ID: 18779728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genomic signatures in T-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?
    Iqbal J; Wilcox R; Naushad H; Rohr J; Heavican TB; Wang C; Bouska A; Fu K; Chan WC; Vose JM
    Blood Rev; 2016 Mar; 30(2):89-100. PubMed ID: 26319391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epstein-Barr virus-positive nodal peripheral T cell lymphomas: clinicopathologic and gene expression profiling study.
    Ha SY; Sung J; Ju H; Karube K; Kim SJ; Kim WS; Seto M; Ko YH
    Pathol Res Pract; 2013 Jul; 209(7):448-54. PubMed ID: 23735590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma.
    Han JJ; O'byrne M; Stenson MJ; Maurer MJ; Wellik LE; Feldman AL; McPhail ED; Witzig TE; Gupta M
    Blood Cancer J; 2018 Nov; 8(11):110. PubMed ID: 30420593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.